References
- 1. C. Ireson, S. Orr, D. J. Jones, R. Verschoyle, C.-K. Lim, J.-L. Luo, L. Howells, S. Plummer, R. Jukes and M. Williams, Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production, Cancer Res.61 (2001) 1058–1064.
- 2. T. N. Almanaa, M. E. Geusz and R. J. Jamasbi, Effects of curcumin on stem-like cells in human esophageal squamous carcinoma cell lines, BMC Complement. Altern. Med.12 (2012) 1–15 DOI: 10.1186/1472-6882-12-195.
- 3. B. B. Aggarwal, S. C. Gupta and B. Sung, Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers, Br. J. Pharmacol.169 (2013) 1672–1692; DOI: 10.1111/bph.12131.
- 4. A. B. Kunnumakkara, P. Anand and B. B. Aggarwal, Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins, Cancer Lett.269 (2008) 199–225; DOI: 10.1016/j.canlet.2008.03.009.
- 5. T.-F. Jiang, Y.-J. Zhang, H.-Y. Zhou, H.-M. Wang, L.-P. Tian, J. Liu, J.-Q. Ding and S.-D. Chen, Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson’s disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy, J. Neuroimmune Pharmacol.8 (2013) 356–369; DOI: 10.1007/s11481-012-9431-7.
- 6. C. N. Conteas, A. M. Panossian, T. T. Tran and H. M. Singh, Treatment of HIV-associated diarrhea with curcumin, Dig. Dis. Sci.54 (2009) 2188–2191; DOI: 10.1007/s10620-008-0597-z.
- 7. L. X. Na, Y. Li, H. Z. Pan, X. L. Zhou, D. J. Sun, M. Meng, X. X. Li and C. H. Sun, Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial, Mol. Nutr. Food Res.57 (2013) 1569–1577; DOI: 10.1002/mnfr.201200131.
- 8. M. Garcia-Alloza, L. Borrelli, A. Rozkalne, B. Hyman and B. Bacskai, Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model, J. Neurochem.102 (2007) 1095–1104; DOI: 10.1111/j.1471-4159.2007.04613.x.
- 9. S. Shishodia, T. Singh and M. M. Chaturvedi, Modulation of Transcription Factors by curcumin, in The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease (Eds. B. B. Aggarwal, Y.-J. Surh and S. Shishodia) (Series: Advances in Experimental Medicine and Biology, Vol. 595), Springer, New York 2007, pp. 27–148.
- 10. N. Handler, W. Jaeger, H. Puschacher, K. Leisser and T. Erker, Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors, Chem. Pharm. Bull.55 (2007) 64–71; DOI: 10.1248/cpb.55.64.
- 11. Y. Bustanji, M. O. Taha, I. M. Almasri, M. A. Al-Ghussein, M. K. Mohammad and H. S. Alkhatib, Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation, J. Enzyme Inhib. Med. Chem.24 (2009) 771–778; DOI: 10.1080/14756360802364377.
- 12. K. E. Sheppard and G. A. McArthur, The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma, Clin. Cancer Res.19 (2013) 5320–5328; DOI: 10.1158/1078-0432.CCR-13-0259.
- 13. Hypercube Inc, HyperChem(TM) Professional 8.014 Hypercube, Gainesville (FL) 2008.
- 14. G. Jones, P. Willett, R.C. Glen, A.R. Leach and R. Taylor, Development and validation of a genetic algorithm for flexible docking, J. Mol. Biol.267 (1997) 727–748; DOI: 10.1006/jmbi.1996.0897.
- 15. S. Kawano, Y. Inohana, Y. Hashi and J.-M. Lin, Analysis of keto-enol tautomers of curcumin by liquid chromatography/mass spectrometry, Chin. Chem. Lett.24 (2013) 685–687; DOI: 10.1016/j.cclet.2013.05.006.